AU
UK
CA
US
IND
NZ
Last update at 2026-06-05T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
Tue 05 Aug 25, 08:01 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -58.57300M | -17.30900M | -29.74400M | -66.89400M | -70.48000M |
| Minority interest | - | - | - | - | - |
| Net income | -61.59600M | -17.91400M | -30.39100M | -66.54600M | -70.48000M |
| Selling general administrative | 112.45M | 91.89M | 76.60M | 74.59M | 70.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 118.49M | 148.15M | 107.73M | 58.38M | 44.22M |
| Reconciled depreciation | 1.00M | 1.16M | 0.71M | 0.68M | 0.59M |
| Ebit | -54.23000M | -8.97500M | -28.97300M | -69.09100M | -73.27700M |
| Ebitda | -53.54600M | -8.92800M | -28.39100M | -66.55900M | -72.68300M |
| Depreciation and amortization | 0.68M | 0.05M | 0.58M | 2.53M | 0.59M |
| Non operating income net other | 0.68M | 0.05M | 0.58M | 2.53M | 2.20M |
| Operating income | -54.23000M | -8.97500M | -28.97300M | -69.09100M | -72.68300M |
| Other operating expenses | 174.47M | 158.21M | 137.59M | 128.38M | 117.19M |
| Interest expense | 3.71M | 4.86M | 1.35M | 0.34M | 0.00000M |
| Tax provision | 0.00000M | 0.60M | - | - | - |
| Interest income | 0.68M | 0.05M | 0.58M | 2.53M | 2.20M |
| Net interest income | -3.02300M | -4.81300M | -0.77100M | 2.20M | 2.20M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | 1.32M | 3.52M | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 3.02M | 0.60M | 0.65M | -0.34800M | 2.20M |
| Total revenue | 120.24M | 149.24M | 108.62M | 59.29M | 44.51M |
| Total operating expenses | 172.72M | 157.13M | 136.70M | 127.47M | 116.91M |
| Cost of revenue | 1.75M | 1.08M | 0.90M | 0.91M | 0.29M |
| Total other income expense net | -4.34300M | -8.33400M | -0.77100M | 2.20M | 2.20M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -58.57300M | -17.91400M | -29.74400M | -66.89400M | -70.48000M |
| Net income applicable to common shares | -58.57300M | -17.91400M | -29.74400M | -66.89400M | -70.48000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 117.22M | 134.28M | 167.33M | 110.38M | 147.57M |
| Intangible assets | 13.88M | 14.95M | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 6.26M | 8.26M | 7.41M | 14.04M | 9.46M |
| Total liab | 145.87M | 147.90M | 136.95M | 76.35M | 93.75M |
| Total stockholder equity | -28.64400M | -13.61600M | 30.37M | 34.03M | 53.81M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 21.16M | 28.06M | 47.27M | 25.50M | 21.50M |
| Common stock | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M |
| Capital stock | 0.17M | 0.17M | 0.17M | 0.17M | 0.17M |
| Retained earnings | -1407.55000M | -1382.45900M | -1323.88600M | -1305.97200M | -1276.22800M |
| Other liab | - | - | 52.73M | 5.04M | 6.50M |
| Good will | - | - | - | - | - |
| Other assets | - | 0.64M | 0.97M | 0.82M | 0.70M |
| Cash | 32.79M | 24.46M | 18.89M | 30.37M | 22.52M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 53.27M | 65.21M | 63.55M | 40.84M | 58.21M |
| Current deferred revenue | 17.04M | 13.51M | 2.60M | 3.02M | 25.29M |
| Net debt | 27.79M | 17.09M | 11.68M | 8.71M | 13.79M |
| Short term debt | 7.92M | 1.13M | 9.89M | 8.62M | 7.27M |
| Short long term debt | 7.23M | - | - | - | - |
| Short long term debt total | 60.58M | 41.55M | 30.57M | 39.09M | 36.31M |
| Other stockholder equity | 1378.72M | 1368.82M | 1354.19M | 1339.83M | 1329.85M |
| Property plant equipment | - | 0.86M | 11.89M | 2.68M | 2.16M |
| Total current assets | 99.27M | 115.90M | 154.47M | 88.98M | 119.00M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -28.56500M | 30.37M | 44.68M | 74.45M |
| Short term investments | 24.15M | 33.75M | 106.08M | 26.95M | 75.56M |
| Net receivables | 30.55M | 40.32M | 15.47M | 15.97M | 10.11M |
| Long term debt | 52.37M | 39.45M | 19.91M | 19.82M | 9.81M |
| Inventory | 5.52M | 9.12M | 6.62M | 1.64M | 1.35M |
| Accounts payable | 7.14M | 22.51M | 3.79M | 3.71M | 4.15M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00800M | -0.15300M | -0.10200M | -0.00400M | 0.02M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.17M | 0.17M | 0.17M | 0.17M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -1382.45900M | -1323.88600M | -1305.97200M | -1276.22800M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 3.06M | 0.64M | 0.97M | 0.82M | 0.70M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 17.96M | 18.38M | 12.86M | 21.39M | 28.56M |
| Capital lease obligations | 0.98M | 2.10M | 10.65M | 19.27M | 26.50M |
| Long term debt total | - | 39.45M | 19.91M | 19.82M | 9.81M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 72.33M | -79.40900M | 48.73M | -22.20100M | 26.07M |
| Change to liabilities | -3.54100M | -0.38100M | 3.42M | -1.05300M | 11.09M |
| Total cashflows from investing activities | 72.78M | -80.03600M | 47.47M | -23.65600M | 24.96M |
| Net borrowings | 19.54M | 19.54M | 9.97M | 9.79M | 9.79M |
| Total cash from financing activities | 6.55M | 62.67M | 12.57M | 11.37M | 71.89M |
| Change to operating activities | -4.38500M | 14.47M | -0.37400M | 1.04M | 2.85M |
| Net income | -58.57300M | -17.91400M | -29.74400M | -66.89400M | -70.48000M |
| Change in cash | 5.57M | -11.48300M | 7.85M | -53.80100M | 38.03M |
| Begin period cash flow | 18.89M | 30.37M | 22.52M | 76.32M | 38.29M |
| End period cash flow | 24.46M | 18.89M | 30.37M | 22.52M | 76.32M |
| Total cash from operating activities | -73.75800M | 5.88M | -52.18500M | -41.51000M | -58.82600M |
| Issuance of capital stock | - | - | 0.00000M | 0.00000M | 67.16M |
| Depreciation | 1.00M | 1.16M | 0.71M | 0.68M | 0.59M |
| Other cashflows from investing activities | 0.89M | - | - | -22.20100M | 26.07M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -2.37700M | -4.87500M | -0.12600M | -0.36600M | -0.83900M |
| Change to account receivables | -24.84800M | 0.50M | -5.86200M | -6.03400M | -4.07700M |
| Sale purchase of stock | 2.12M | 4.78M | 2.60M | 1.58M | 71.89M |
| Other cashflows from financing activities | 4.43M | 62.67M | 12.57M | 11.37M | 4.73M |
| Change to netincome | 13.07M | 12.91M | 7.30M | 9.12M | 7.70M |
| Capital expenditures | 0.45M | 0.63M | 1.26M | 1.46M | 1.11M |
| Change receivables | -24.84800M | 0.50M | -5.86200M | -6.03400M | -4.07700M |
| Cash flows other operating | 1.58M | 5.63M | -27.75600M | 24.11M | -2.05100M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 5.57M | -11.48300M | 7.85M | -53.80100M | 38.03M |
| Change in working capital | -29.04900M | 9.72M | -30.32200M | 16.66M | 4.12M |
| Stock based compensation | 12.38M | 9.49M | 7.30M | 9.12M | 7.70M |
| Other non cash items | 0.48M | 3.14M | -0.12200M | -1.07300M | -0.76600M |
| Free cash flow | -74.20800M | 5.25M | -53.44700M | -42.96500M | -59.93200M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals Inc |
-0.32 1.06% | 29.93 | - | - | 1.82 | 31.64 | 1.82 | -12.5068 |
| NVO Novo Nordisk A/S |
-0.79 1.81% | 42.96 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.6937 1.57% | 43.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.09 1.15% | 446.83 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
6.72 1.07% | 635.45 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.
611 Gateway Blvd, South San Francisco, CA, United States, 94080
| Name | Title | Year Born |
|---|---|---|
| Mr. Raul R. Rodriguez | Pres, CEO & Director | 1961 |
| Mr. Dean L. Schorno CPA | Exec. VP & CFO | 1963 |
| Dr. Wolfgang Dummer M.D., Ph.D. | Exec. VP & Chief Medical Officer | 1966 |
| Mr. David A. Santos | Exec. VP & Chief Commercial Officer | 1963 |
| Mr. Joseph Lasaga | Exec. VP of Corp. Devel. | 1975 |
| Ms. Julie Patel | Sr. VP of HR | NA |
| Dr. Esteban S. Masuda | Exec. VP of Research | 1962 |
| Mr. Tarek Sallam | VP of Marketing | NA |
| Mr. Raul R. Rodriguez | President, CEO & Director | 1961 |
| Mr. Dean L. Schorno CPA | Executive VP & CFO | 1963 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...